Patents by Inventor Kevin Wayne Kuntz

Kevin Wayne Kuntz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38
    Publication number: 20220242862
    Abstract: The present invention relates to compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 4, 2022
    Inventors: Jennifer Downing, Kevin Wayne Kuntz, Laurie B. Schenkel, Melissa Marie Vasbinder
  • SCREENING METHODS FOR PARP MODULATORS
    Publication number: 20220206008
    Abstract: The present disclosure is related to methods of identifying Poly(ADP-ribose) polymerases (PARP) inhibitors, and the methods of using PARP probes.
    Type: Application
    Filed: March 17, 2022
    Publication date: June 30, 2022
    Inventors: Timothy J.N. Wigle, Danielle J. Blackwell, Kevin Wayne Kuntz, Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger
  • Combination therapy for treating cancer
    Patent number: 11370781
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: June 28, 2022
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah Kathleen Knutson, Kevin Wayne Kuntz
  • SOLID FORMS OF A PARP7 INHIBITOR
    Publication number: 20220162196
    Abstract: The present invention relates to solid forms of the poly(ADP-ribose) polymerase 7 (PARP7) inhibitor 5-[[(2S)-1-(3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy)propan-2-yl]amino]-4-(trifluoromethyl)-2,3-dihydropyridazin-3-one, and salts thereof, including methods of preparation thereof, where the inhibitor is useful in the treatment of cancer.
    Type: Application
    Filed: April 28, 2020
    Publication date: May 26, 2022
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz, Jun Xu, Meng Jiang, Xin He
  • Screening methods for PARP modulators
    Patent number: 11293927
    Abstract: The present disclosure is related to methods of identifying Poly(ADP-ribose) polymerases (PARP) inhibitors, and the methods of using PARP probes.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: April 5, 2022
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Timothy J. N. Wigle, Danielle J. Blackwell, Kevin Wayne Kuntz, Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger
  • SMYD INHIBITORS
    Publication number: 20210198252
    Abstract: The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such a SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: May 1, 2020
    Publication date: July 1, 2021
    Inventors: Megan Alene Cloonan Foley, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
  • AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS
    Publication number: 20210198277
    Abstract: The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: November 20, 2020
    Publication date: July 1, 2021
    Inventors: John Emmerson CAMPBELL, Kenneth William DUNCAN, Megan Alene FOLEY, Darren Martin HARVEY, Kevin Wayne KUNTZ, James Edward John MILLS, Michael John MUNCHHOF
  • Pyridazinones as PARP7 inhibitors
    Patent number: 11014913
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: May 25, 2021
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • Quinazolinones as PARP14 inhibitors
    Patent number: 11008308
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: May 18, 2021
    Assignee: Ribon Therapeutics Inc.
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger
  • SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR
    Publication number: 20210137936
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Application
    Filed: September 25, 2020
    Publication date: May 13, 2021
    Inventors: Kevin Wayne KUNTZ, Kuan-Chun HUANG, Hyeong Wook CHOI, Kristen SANDERS, Steven MATHIEU, Arani CHANDA, Francis FANG
  • PYRIDAZINONES AS PARP7 INHIBITORS
    Publication number: 20210130342
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: October 29, 2020
    Publication date: May 6, 2021
    Inventors: Nicholas Robert Perl, Melissa Marie Vasbinder, Kevin Wayne Kuntz
  • SUBSTITUTED BENZENE COMPOUNDS
    Publication number: 20210060027
    Abstract: The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: July 9, 2020
    Publication date: March 4, 2021
    Inventors: Kevin Wayne Kuntz, John Emmerson Campbell, Masashi Seki, Syuji Shirotori, Wataru Itano, Wanjun Zheng
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20210053948
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: August 5, 2020
    Publication date: February 25, 2021
    Inventors: Heike KEILHACK, Sarah Kathleen KNUTSON, Kevin Wayne KUNTZ
  • HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38
    Publication number: 20210032251
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 4, 2021
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • PYRIDAZINONES AS PARP7 INHIBITORS
    Publication number: 20210024502
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: August 11, 2020
    Publication date: January 28, 2021
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • HYDROCHLORIDE SALT FORM FOR EZH2 INHIBITION
    Publication number: 20210017163
    Abstract: Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.
    Type: Application
    Filed: June 3, 2020
    Publication date: January 21, 2021
    Inventors: Kevin Wayne KUNTZ, Hyeong Wook CHOI, Steven MATHIEU, Kristen SANDERS, Arani CHANDA
  • Pyridazinones as PARP7 inhibitors
    Patent number: 10870641
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: December 22, 2020
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent number: 10821113
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 3, 2020
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • Combination therapy for treating cancer
    Patent number: 10787440
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: September 29, 2020
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah Kathleen Knutson, Kevin Wayne Kuntz
  • QUINAZOLINONES AS PARP14 INHIBITORS
    Publication number: 20200247788
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: January 6, 2020
    Publication date: August 6, 2020
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger